Cannabix Launches Commercial Rollout of Marijuana Breath Test
Event summary
- Cannabix Technologies Inc. began commercial rollout of its Marijuana Breath Test (MBT) system on March 16, 2026.
- The MBT system detects delta-9 THC in breath within approximately 4 hours of consumption at levels above 5 pg/L.
- Peer-reviewed validation of the MBT system was published in the Journal of Analytical Toxicology in March 2026.
- Cannabix has established manufacturing procedures, partnerships, and QA/QC processes for MBT hardware.
- The MBT system follows a recurring revenue model with disposable Breath Cartridges generating ongoing revenue.
The big picture
Cannabix's commercial launch of the Marijuana Breath Test addresses a critical gap in detecting recent cannabis use, providing a non-invasive solution for employers and safety-sensitive industries. As legalized recreational and medical marijuana use expands globally, accurate detection of recent use via breath is becoming essential for maintaining fairness and informed decision-making. The strategic partnership with Omega Laboratories, a global leader in forensic drug testing, further strengthens Cannabix's position in the market.
What we're watching
- Market Adoption
- The pace at which employers and law enforcement agencies adopt the MBT system will determine its commercial success.
- Regulatory Compliance
- Whether the MBT system can navigate evolving legal frameworks for cannabis testing in different jurisdictions.
- Competitive Positioning
- How Cannabix can sustain its lead in breath-based cannabis detection against potential competitors.
Related topics